2型糖尿病合并非酒精性脂肪肝患者血清25-(OH)D水平与肝纤维化程度的相关性

Value of Serum 25-(OH)D in Evaluating the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with NAFLD

【目的】探讨2型糖尿病合并非酒精性脂肪肝(NAFLD)患者血清25-羟基维生素D[25-(OH)D]水平与肝纤维化程度的相关性。【方法】本院收治的60例2型糖尿病合并NAFLD患者为观察组,另外选取同期收治的60例2型糖尿病患者为对照组。比较两组血清25-(OH)D、空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbAlc)水平的差异及不同肝纤维化分期患者25-(OH)D水平的差异;同时分析25-(OH)D水平与肝纤维化分期的相关性。【结果】两组FPG、2hPG、HbAlc水平相比较差异无显著性(P>0.05);观察组25-(OH)D水平显著低于对照组,且差异有显著性(P<0.05)。不同肝纤维化分期患者25-(()H)D水平对比为Si期〉S2期>33期>5.,期,且各期患者之间相比较差异均有显著性(P<5)。25-(OH)D水平与肝纤维化分期呈负相关(P<0.05)。【结论】2型糖尿病合并NAFLD患者25-(OH)D水平明显降低,且与肝纤维化分期呈负相关,其能够为患者肝纤维化分期评估提供参考,具有较高的临床应用价值。

【Objective】To explore the value of serum 25-(OH)D in evaluating the degree of liver fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease(NAFLD).【Methods】In this study,60 patients with type 2 diabetes mellitus complicated with NAFLD were selected as the observation group,and 60 patients with type 2 diabetes mellitus admitted in the same period were selected as the control group.The serum levels of 25-(()H)D,FPG,2hPG and HbAlc were compared between the two groups.Meanwhile,Spearman correlation coefficient was used to analyze the correlation between 25-(OH)D level and stages of liver fibrosis.【Results】There was no significant difference in the levels of FPG,2hPG and HbAlc between the two groups(P>0.05).The level of 25-(OH)D in the observation group was significantly lower than that that in the control group(P<0.05).Levels of 25-(OH)D in patients of the observation group were significantly different from their stages of liver fibrosis:Si>S2>S3>S4(P<0.05).The correlation analysis showed that the level of 25-(()H)D was negatively correlated with the stages of liver fibrosis(P<0.05).【Conclusion】The level of 25-(OH)D in patients with type 2 diabetes complicated with NAFLD is significantly reduced.The level of 25-(OH)D is negatively correlated with the stages of liver fibrosis,which can provide reference to evaluate the stagevS of liver fibrosis in patients with type 2 diabetes mellitus and NAFLD.